What FDA’s 2026 Warning Letters to “Research Peptide” Sellers Actually Say

Released: October 15, 2026·Last reviewed: October 15, 2026·Methodology v4.1

Which sellers did FDA write to in 2026?

Seven letters from FDA’s drug center (CDER) are addressed to companies that sell peptides online. Five carry the same date, August 24, 2026, and were posted with pages “current as of” September 1. All five say FDA reviewed the seller’s website in July 2026. Two earlier letters went out on March 31 and June 17.

Product names are as quoted by FDA, including the sellers’ own code names. We did not search FDA’s warning-letter database exhaustively; other 2026 letters may exist.

What did the five August letters name most often?

The August letters read almost like one letter sent five times. Every one names retatrutide, semaglutide, tesamorelin and PT-141. Four of five add tirzepatide, SS-31 and bacteriostatic water.

The pattern matters because several of these molecules have approved versions. Semaglutide is Ozempic, Wegovy and Rybelsus; tirzepatide is Mounjaro and Zepbound; tesamorelin is Egrifta; bremelanotide is Vyleesi; elamipretide is Forzinity. A “research” vial with the same name is none of those products. The letters say plainly that “no approved applications” are in effect for the products as sold.

Why did the “research use only” label fail?

The labels are the sellers’ legal shield, and FDA addressed them directly. Four of the five August letters carry the same footnote: “Despite statements on your product labeling marketing your products for ‘research use only’ and ‘not for human consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.” The fifth, to NuScience, quotes its label “for laboratory, research, and analytical use” and reaches the same conclusion.

FDA gave two kinds of evidence. The first is the product copy. On one site FDA quoted retatrutide described as “Investigated for influence on appetite regulation and satiety pathways” and semaglutide as “Explored for potential impact on body weight and metabolic health”. Wording that hedges with “studied for” and “explored for” still describes an effect on the body, and that is what makes something a drug under section 201(g)(1).

The second is the bacteriostatic water. FDA wrote that selling it with the peptides “demonstrates that you intend for your ‘Bac water’ to be used in combination for injection,” and that the sellers were “providing the means to prepare an injectable drug for human administration.” Laboratories that genuinely run research do not need a retail seller to bundle the diluent.

What happens to the sellers now?

Each letter asks for a written reply “within fifteen (15) business days of receipt” describing the corrective steps. It warns that failure to fix the violations “may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.” A warning letter is FDA’s formal notice, not a court ruling, and FDA’s site does not show the replies.

Worked examples

Example 1: how much of the catalogue is GLP-1. The five August letters name 36 products in total (6 + 7 + 7 + 9 + 7). Sixteen are GLP-1-class drugs: semaglutide, tirzepatide, retatrutide, survodutide and mazdutide (2 + 3 + 3 + 5 + 3). That is 16 of 36, or 44%. The letters are about weight-loss demand as much as about “peptides”.

Example 2: the timeline. FDA says it reviewed the five websites in July 2026. The letters are dated Monday, August 24, and the pages were current as of September 1, eight days later. Fifteen business days is at least three calendar weeks, so the earliest replies were due in mid-September.

Example 3: a product you might be offered. Suppose a site sells “GLP-3 RT, 10 mg, research use only” with a vial of bacteriostatic water in the cart. Check it against the letters: the product is retatrutide, named in 5 of 5 August letters; it has no U.S. approval; FDA’s GLP-1 page (October 1, 2026) says it “cannot be used in compounding under federal law”; and the bundled water is the exact pattern FDA described. Four checks, four failures.

What this means for you

• A code name is a warning sign. “GLP-1 S”, “GLP-2 T” and “GLP-3 RT” are how these sellers labelled semaglutide, tirzepatide and retatrutide.
• Look for a prescriber and a pharmacy. A lawful route names both. Our peptide provider checklist shows how to check each.
• Know which molecules have an approved version. See tesamorelin, semaglutide and tirzepatide; retatrutide has none.
• Absence from a letter is not approval. BPC-157 appears in none of these letters, and it is still not on the 503A list; see peptide legal status.

The difference between a research chemical and a prescription is explained in research peptides vs prescription peptides.